In the Lab, CRISPR Disables the Extra Chromosome Causing Down Syndrome

November 19, 2026

In the United States, researchers have combined the CRISPR/Cas9 gene-editing scissors with a natural mechanism to neutralize the genetic cause of Down syndrome. Within affected cells, scientists have managed to deactivate the extra chromosome responsible for the syndrome.

Putting the extra chromosome 21 to sleep

As a reminder, Down syndrome (trisomy 21) is a genetic anomaly characterized by the presence of an extra chromosome 21 (three instead of two) in the cells. The condition involves intellectual disability that varies among individuals, as well as distinctive facial features and a higher risk of malformations. In the absence of treatment, only regular medical follow-up and early intervention are possible.

As evidenced by a publication in the Proceedings of the National Academy of Sciences (PNAS) on April 13, 2026, Beth Israel Deaconess Medical Center in Boston (United States) may have discovered a credible solution to overcome the syndrome. The neurologists have demonstrated that it is possible to neutralize the genetic error at the root of the disease.

The authors of the study successfully attempted to tackle the famous extra chromosome 21, drawing inspiration from a natural process: in women, the XIST gene naturally inactivates one of the two X chromosomes. The researchers then had the idea to use the CRISPR/Cas9 gene-editing scissors to implant the gene into the third copy of chromosome 21 in the cells affected by the syndrome. According to the results, the chromosome goes to sleep and stops sending disruptive signals to the body.

Chromosomal therapy becomes a reality

For the investigators behind these works, the discovery represents a true leap forward. Indeed, whereas previous methods could not reach a sufficient number of cells, the technique involving the XIST gene and the CRISPR/Cas9 scissors offers the possibility of affecting between 20 and 40% of targeted cells. Moreover, the procedure has undergone calibration to avoid impacting the other two copies of chromosome 21 and thus to prevent doing more harm than good.

These highly promising results show that chromosomal therapy is indeed a reality, which now needs to move beyond laboratories. However, given that the protocol can be scaled up, neurologists express enthusiasm. Nevertheless, the path still seems quite long before the treatment appears in pharmacies. Nonetheless, the researchers do not exclude that, in the long term, it may be possible to defeat other chromosomal diseases—the aneuploidies.

“ Our results demonstrate a partial transcriptional correction of the dosage of trisomic genes and offer a scalable and targeted platform for chromosomal therapy in Down syndrome and other aneuploidies.”, one can read in the study.

Ongoing research

The next step for the scientists involves testing on rodents, with the objective of identifying the ideal moment to intervene and determining whether it might be possible to act during pregnancy (in utero). The challenge will also be to understand whether a complete or partial silencing of the extra chromosome could potentially improve patients’ cognitive abilities, as well as their overall health. It should be noted that some parallel studies suggest that a small portion of the XIST gene could be sufficient, implying easier delivery to brain cells.

In the meantime, parent associations and families are finding renewed hope and are pleased to see that the illness is not forgotten by science. By the way, worldwide, about eight million people carry the syndrome, and their average life expectancy generally ranges between 50 and 60 years in developed countries.

Article prepared with the help of AI · Our method

Sindre Halvorsen

I write about space exploration, frontier science and the technologies that are quietly shaping the future. From Norway, I follow the missions, discoveries and ideas that connect life on Earth with what lies beyond it. My goal is to make complex subjects clear, useful and worth paying attention to.